Development of iPS Cells for Treatment of Hemoglobinopathies

开发用于治疗血红蛋白病的 iPS 细胞

• 批准号: 8532884
• 负责人: YUET Wai KAN
• 金额: $ 125.56万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8532884
• 关键词: Address; Adenoviruses; Advisory Committees; Africa; B-Lymphocytes; California; Cell Line; Cell Therapy; Cell Transplantation; Cells; Cellular biology; Collaborations; Complement; Complementary DNA; Data; Dedications; Development; Disease; Double-Stranded RNA; Economic Burden; Elements; Excision; Far East; Generations; Genes; Goals; Grant; Healthcare Systems; Hematopoietic; Hematopoietic System; Hematopoietic stem cells; Hemoglobinopathies; Hereditary Disease; Individual; Inherited; Integrase; Link; Mediating; Medical center; Methods; Middle East; Modification; Molecular Biology; Mutation; Oligonucleotides; Patients; Peptides; Plasmids; Polynucleotides; Quality of life; RNA; Regenerative Medicine; Research Institute; Resources; Safety; Science; Services; Sickle Cell; Sickle Cell Anemia; Somatic Cell; Stem Cell Research; Stem cell transplant; Stem cells; Structure of thyroid parafollicular cell; System; Testing; Thalassemia; Time; Xeno; Zinc Fingers; base; beta Globin; beta Thalassemia; c-Myc Staining Method; disease-causing mutation; gene therapy; homologous recombination; improved; induced pluripotent stem cell; nuclease; programs; reconstitution; social

DESCRIPTION (provided by applicant): The proposed POI is a multi-institutional grant that will develop a stem cell based therapy for the treatment of sickle cell disease (SCD) and ¿-thalassemia (¿-thal) as well as other hemoglobinopathies, using patient derived somatic cells and reprogramming them into induced pluripotent stem (IPS) cells that will have their mutations corrected and ultimately differentiated into hematopoietic stem cells (HSCs) to reconstitute the patient's hematopoietic system. Development of an effective cellular therapy for the treatment of hemoglobinopathies, the most common inherited diseases worldwide, would significantly improve the quality of life of individuals afflicted with SCD and B-thalassemia that are common among the peoples of Africa, the Mediterranean, the Middle East, and Asia as well as their descendents in the U.S. This proposal will test the hypothesis that an effective cellular and genetic therapy for these diseases can be achieved in the context of this PPG through the generation, modification, and the hematopoietic differentiation of patient derived iPS cells. This will be accomplished through the following Projects: Project 1 will involve the conversion of a patient's somatic cells into IPS cells using phiC31 Integrase-mediated, sequence-specific integration of a plasmid carrying 2A peptide linked Oct4, Sox2, Klf4, and cMyc reprogramming cDNAs or by using small activating double stranded RNA (saRNA) to transiently enhance the expression of these reprogramming genes. Project 2 will involve correction of the disease causing mutations in the somatic cells and the iPS cells by sequence specific modification using either classical homologous recombination (HR) or by oligo/polynucleotide-based small fragment homologous replacement (SFHR) in the presence or absence of targeted zinc finger nucleases (ZFNs) or other meganucleases. Project 3 will involve exposure of uncorrected and corrected iPS cells to conditions to direct hematopoietic differentiation to generate HSCs which have the capacity to engraft and reconstitute the hematopoietic system. In the course of this PPG, all Projects will develop xeno-free systems to optimize safety. The science in the Projects will be augmented by an administrative (Core A) and 2 scientific Cores: Core B: Cell and Molecular Biology, and Core C: Cell Transplantation and Analysis.

描述(申请人提供)：拟议的POI是一项多机构赠款，将开发一种基于干细胞的疗法，用于治疗镰状细胞病(SCD)、地中海贫血(地中海贫血)以及其他血红蛋白疾病，使用患者来源的体细胞，并将它们重新编程为诱导的多能干细胞(IPS)，这些细胞的突变将得到纠正，并最终分化为造血干细胞(HSCs)，以重建患者的造血系统。开发一种有效的细胞疗法来治疗血红蛋白病，这是世界上最常见的遗传性疾病，将显著改善患有SCD和B-地中海贫血的患者及其在美国的后代的生活质量。这项提议将检验这样一种假设，即在这种PPG的背景下，可以通过患者来源的iPS细胞的生成、修饰和造血分化来实现对这些疾病的有效的细胞和基因治疗。这将通过以下项目完成：项目1将涉及将患者的体细胞转化为IPS细胞，使用phiC31整合酶介导的、序列特定的携带连接Oct4、Sox2、Klf4和cMyc重编程cDNA的2A肽的质粒，或通过使用小的激活双链RNA(SARNA)来瞬时增强这些重编程基因的表达。项目2将涉及通过使用经典的同源重组(HR)或在存在或不存在靶向锌指核酸酶(ZFN)或其他巨核酸酶的情况下通过基于寡/多核苷酸的小片段同源替换(SFHR)进行序列特异性修改来纠正引起体细胞和iPS细胞突变的疾病。项目3将涉及将未校正和已校正的iPS细胞暴露在引导造血分化的条件下，以产生具有植入和重建造血系统能力的造血干细胞。在这一PPG过程中，所有项目都将开发无异物系统，以优化安全性。项目中的科学将增加一项行政管理(核心A)和两项科学核心：核心B：细胞和分子生物学，核心C：细胞移植和分析。